{"id":49206,"date":"2022-10-05T19:01:59","date_gmt":"2022-10-05T17:01:59","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kidney-transplant-rejection-drugs-2022-update-players-include-astellas-pharma-bristol-myers-squibb-cynata-therapeutics-and-eledon-pharmaceuticals-researchandmarkets-com\/"},"modified":"2022-10-05T19:01:59","modified_gmt":"2022-10-05T17:01:59","slug":"kidney-transplant-rejection-drugs-2022-update-players-include-astellas-pharma-bristol-myers-squibb-cynata-therapeutics-and-eledon-pharmaceuticals-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kidney-transplant-rejection-drugs-2022-update-players-include-astellas-pharma-bristol-myers-squibb-cynata-therapeutics-and-eledon-pharmaceuticals-researchandmarkets-com\/","title":{"rendered":"Kidney Transplant Rejection Drugs 2022 Update – Players Include Astellas Pharma, Bristol-Myers Squibb, Cynata Therapeutics and Eledon Pharmaceuticals – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Kidney Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis report provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape.\n<\/p>\n

\nKidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.\n<\/p>\n

\nReport Highlights<\/strong>\n<\/p>\n

\nThe report provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\n<\/p>\n

\nThe Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies \/Universities \/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 10, 7, 21, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.\n<\/p>\n

\nKidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company\/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.\n<\/p>\n

\nScope<\/strong>\n<\/p>\n